We also aimed to further observe whether PPARγ agonists could reverse vascular endothelial dysfunction in hypercholesterolemia and, if possible, to determine whether or not this was related to the regulation of vascular MPO and subsequent restoration of NO bioavailability. This evidence concerns the gene MPO and Hypercholesterolemia.